Proteomic Signature of Thrombin-Activated Platelets After In Vivo Nitric Oxide–Donor Treatment | Zendy

Esther Peña | Zendy; Teresa Padró | Zendy; Blanca Molins | Zendy; Gemma Vilahur | Zendy; Lina Badimón | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Proteomic Signature of Thrombin-Activated Platelets After In Vivo Nitric Oxide–Donor Treatment

Author(s) -

Esther Peña,

Teresa Padró,

Blanca Molins,

Gemma Vilahur,

Lina Badimón

Publication year - 2011

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.111.231852

Subject(s) - thrombin , platelet , chemistry , platelet activation , in vivo , western blot , nitric oxide , pharmacology , thrombin receptor , biochemistry , medicine , biology , microbiology and biotechnology , organic chemistry , gene

Growing insight into the antiplatelet properties of new nitric oxide (NO) donors has expanded their potential use in cardiovascular diseases. As such, we reported that oral administration of a new exogenous NO donor (LA419) induced significant inhibition of platelet deposition on damaged vascular wall without provoking hypotension in an in vivo experimental model. Thrombin is one of the major triggers of platelet deposition and thrombosis on injured vessels; however, the effects of NO on thrombin-induced platelet activation are not fully known. Here, our aim was to investigate the inhibitory effects of exogenous NO administration on the major changes in platelet proteins induced by thrombin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research